세계의 트라넥삼산 시장 규모는 2024년 10억 3,747만 달러에서 예측 기간 중 CAGR 5.38%로 크게 성장하며, 2035년에는 18억 6,199만 달러 규모에 달할 것으로 예측됩니다.
세계의 트라넥삼산시장은 의료, 제약, 미용 분야에서 효과적인 지혈제에 대한 수요가 증가함에 따라 빠르게 성장하고 있습니다. 트라넥삼산은 수술, 외상, 월경 이상으로 인한 과다 출혈을 예방하기 위해 자주 사용되고 있으며, 병원, 클리닉, 재택의료, 응급의료 현장에서 널리 채택되고 있습니다. 또한 피부과 및 미용 분야, 특히 색소침착 치료에서 트라넥삼산의 장점이 널리 알려지면서 시장이 확대되고 있습니다.
또한 약물의 제제 기술 및 전달 메커니즘의 혁신으로 생체 이용률 및 치료 효과가 향상되어 시장 환경이 크게 변화하고 있습니다. 리포좀 및 나노입자 기반 제제 등 혁신적인 트라넥삼산 제제는 치료 효과를 높이면서 부작용을 줄이는데 기여하고 있습니다. 또한 다른 활성 성분을 결합한 병용 요법의 개발로 의료 및 미용 분야에서 트라넥삼산의 적응증이 확대되고 있는 것도 시장 성장을 가속하고 있습니다.
지역별 분석
세계 트라넥삼산 시장에서 북미는 첨단화된 의료 인프라, 높은 수술 건수, 출혈 관리에 대한 인식이 높아지면서 시장을 주도하고 있습니다. 미국과 캐나다는 외상 관련 부상 증가, 규제 정책 지원, 외과적 치료 확대 등으로 인해 트라넥삼산 채택에 있으며, 선두를 달리고 있습니다.
유럽은 성숙한 규제, 광범위한 임상 사용, 정부의 강력한 지원 및 확립된 제약 제조 능력을 갖춘 성숙한 규제 지역입니다. 유럽의약품청(EMA)과 각국 규제 당국은 트라넥삼산을 다양한 의료 용도로 승인하여 의료기관에서 표준화된 사용을 보장하고 있습니다. 아시아태평양은 빠른 성장세를 보이고 있으며, 제약 생산 확대, 외상 발생 건수 증가, 모자보건에 대한 관심 증가, 수술 건수 증가 등이 성장을 촉진하고 있습니다.
세계의 트라넥삼산 시장을 조사했으며, 시장의 정의와 개요, 시장 성장에 대한 각종 영향요인의 분석, 시장 규모 추이·예측, 각종 구분·지역/주요 국가별 내역, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.
Global Tranexamic Acid Market Research Report By Formulation Type (Oral Tablets, Injectable Solutions, Topical Applications), By Application (Post-Surgical Bleeding, Menorrhagia, Trauma Cases, Dental Procedures), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospitals, Clinics, Home Care Settings), By Dosage Form (Low Dosage, Standard Dosage, High Dosage) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) Forecast to 2035
The Global Tranexamic Acid Market is anticipated to experience substantial growth during the review period, with a compound annual growth rate (CAGR) of 5.38%. It is anticipated that the market will attain a value of USD 1,861.99 million by the conclusion of the forecast period (2025-2035), with an estimated value of USD 1,037.47 million in 2024.
The global tranexamic acid market is expanding at a rapid pace, primarily due to the increasing demand for hemostatic agents that are effective in medical, pharmaceutical, and cosmetic applications. Tranexamic acid is being used more frequently to prevent excessive bleeding during surgeries, trauma cases, and menstrual disorders, which is promoting its widespread adoption in hospitals, clinics, home care, and emergency care settings. Furthermore, the market is expanding due to the increasing recognition of the advantages of tranexamic acid in dermatology and cosmetics, particularly for the treatment of hyperpigmentation.
The market landscape is being transformed by technological advancements in drug formulations and delivery mechanisms, which have enabled enhanced bioavailability and therapeutic efficacy. Innovative formulations of tranexamic acid, including liposomal and nanoparticle-based formulations, are improving treatment outcomes while diminishing adverse effects. Furthermore, the market is experiencing growth as a result of the expansion of the scope of tranexamic acid in medical and aesthetic applications through the development of combination therapies that incorporate other active ingredients.
In 2024, the oral segment held a market share of 47.67% based on Formulation Type and is anticipated to grow at a compound annual growth rate (CAGR) of 5.83% during the forecast period. This is primarily motivated by its broad accessibility, affordability, and convenience. The substantial market share of oral tablets is a result of their widespread prescription for conditions such as excessive menstrual bleeding and surgical bleeding prevention.
In 2024, the hospitals & clinics segment held a market share of 45.25% based on End User and is anticipated to grow at a compound annual growth rate (CAGR) of 5.23% during the forecast period. The high volume of surgical procedures, trauma cases, and critical care treatments that necessitate tranexamic acid for haemorrhage management is the reason for this growth.
Analysis of the Region
In the global tranexamic acid (TXA) market, North America is the dominant region due to its advanced healthcare infrastructure, high volume of surgical procedures, and growing awareness of blood loss management. The United States and Canada have been at the forefront of TXA adoption as a result of the increasing number of trauma-related injuries, supportive regulatory policies, and the expansion of surgical interventions.
Europe is a mature and well-regulated TXA market, characterized by pervasive clinical adoption, strong government support, and well-established pharmaceutical manufacturing capabilities. TXA has been certified for a variety of medical applications by the European Medicines Agency (EMA) and national regulatory bodies, thereby guaranteeing standardized usage across healthcare institutions. The Asia-Pacific (APAC) region is experiencing rapid expansion in the tranexamic acid (TXA) market, which is being driven by expanding pharmaceutical production, high trauma incidences, rising maternal healthcare concerns, and increasing surgical volumes. Countries such as Germany are among those in this region. The adoption of TXA is being led by countries such as China, India, Japan, South Korea, and Australia, which are benefiting from an increasing number of clinical applications, growing awareness about blood loss management, and rising healthcare investments.
Pfizer Inc., Fresenius Kabi AG, Teva Pharmaceuticals, Maxwellia Ltd, Aurobindo Pharma, Sun Pharma, Apotex Inc, Ferring Pharmaceuticals, Amring Pharmaceuticals Inc., and Exela Pharma Sciences are among the notable participants in the industry.